Wedbush Reiterates Outperform as Outerwall (OUTR) Looks to Maximize Value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Upgrades Outerwall Inc. (OUTR) to Neutral
March 15, 2016 8:14 AM EDTRoth Capital upgraded Outerwall Inc. (NASDAQ: OUTR) from Sell to Neutral.
For an analyst ratings summary and ratings history on Outerwall Inc. click here. For more ratings news on Outerwall Inc. click here.
Shares of Outerwall Inc. closed at $34.39 yesterday.
... MoreCurrent Outerwall (OUTR) Multiple Implies No Takeout Premium - B. Riley
March 15, 2016 7:13 AM EDTB. Riley analyst, Eric Wold raised his PT to $50 from $42 after Outerwall's (NASDAQ: OUTR) Board initiated a process to explore both strategic and financial alternatives to boost shareholder value.
Shares of OUTR have declined 47% since management announced plans to return 75-100% of FCF to... More
After-Hours Stock Movers 03/14: (CPXX) (SZYM) (ESI) Higher; (IMMU) (MNKD) (NVIV) Lower (more...)
March 14, 2016 6:09 PM EDTCelator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.
Solazyme, Inc. (Nasdaq: SZYM) 29.5% HIGHER; has signed a definitive multi-year global supply agreement with Unilever.... More
Outerwall (OUTR) Raises Quarterly Dividend 100% to $0.60; 7% Yield
March 14, 2016 4:08 PM EDTOuterwall (NASDAQ: OUTR) declared a quarterly dividend of $0.60 per share, or $2.4 annualized. This is a 100% increase from the prior dividend of $0.30.
The dividend will be payable on June 21, 2016, to stockholders of record on June 7, 2016, with an ex-dividend date of June 3,... More
Outerwall (OUTR) to Explore Strategic And Financial Alternatives
March 14, 2016 4:06 PM EDTOuterwall Inc. (Nasdaq: OUTR) today announced that its Board of Directors has initiated a process to explore strategic and financial alternatives to maximize shareholder value. Outerwall has retained Morgan Stanley & Co. LLC as its financial advisor, and Perkins Coie LLP as its legal advisor to assist in this process.
In addition, the Company today reaffirmed the Board and management team's commitment to managing Outerwall's businesses for profitability and cash flow and focusing on expense management, operational efficiencies and network optimization, with the... More
